Navidea President, Dr. Mark Pykett, to Participate in Panel Discussion on Companion Diagnostics at BIO CEO
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that its President and Chief Executive Officer, Dr. Mark Pykett, will participate in an industry panel discussion on companion diagnostics development on Tuesday, February 14, 2012 at 10:30 AM EST as part of the 14th Annual BIO CEO Conference at the Waldorf-Astoria in New York City.
The moderated panel discussion, titled, “Drugs Need Friends Too – Companion Diagnostics & Drug Development,” will feature biopharmaceutical executives analyzing key elements of the development and collaboration process, including the regulatory environment, a global marketplace overview and collaborations between industry and academia. The panel will also focus on the future of diagnostics, and the role of novel technologies that are expected to provide better patient selection, optimized target expression and the utility of multiple mechanisms in the diagnostic process.
Additional details regarding the presentation can be accessed at http://www.bio.org/node/4975.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScan™ – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
Navidea Biopharmaceuticals, Inc.
Brent Larson,
614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released February 13, 2012